Acute On Chronic Liver Failure - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Acute On Chronic Liver Failure - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Acute On Chronic Liver Failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Acute On Chronic Liver Failure: Overview
Acute-on-chronic liver failure (ACLF) is a syndrome characterised by acute decompensation of chronic liver disease associated with organ failures and high short-term mortality. Alcohol and chronic viral hepatitis are the most common underlying liver diseases. Up to 40%–50% of the cases of ACLF have no identifiable trigger; in the remaining patients, sepsis, active alcoholism and relapse of chronic viral hepatitis are the most common reported precipitating factors. An excessive systemic inflammatory response seems to play a crucial role in the development of ACLF. Using a liver-adapted sequential organ assessment failure score, it is possible to triage and prognosticate the outcome of patients with ACLF. The course of ACLF is dynamic and changes over the course of hospital admission.
'Acute On Chronic Liver Failure - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute On Chronic Liver Failure pipeline landscape is provided which includes the disease overview and Acute On Chronic Liver Failure treatment guidelines. The assessment part of the report embraces, in depth Acute On Chronic Liver Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute On Chronic Liver Failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Acute On Chronic Liver Failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute On Chronic Liver Failure Emerging Drugs
Further product details are provided in the report……..
Acute On Chronic Liver Failure: Therapeutic Assessment
This segment of the report provides insights about the different Acute On Chronic Liver Failure drugs segregated based on following parameters that define the scope of the report, such as:
Acute On Chronic Liver Failure: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute On Chronic Liver Failure therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute On Chronic Liver Failure drugs.
Acute On Chronic Liver Failure Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Acute On Chronic Liver Failure - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Acute On Chronic Liver Failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Acute On Chronic Liver Failure: Overview
Acute-on-chronic liver failure (ACLF) is a syndrome characterised by acute decompensation of chronic liver disease associated with organ failures and high short-term mortality. Alcohol and chronic viral hepatitis are the most common underlying liver diseases. Up to 40%–50% of the cases of ACLF have no identifiable trigger; in the remaining patients, sepsis, active alcoholism and relapse of chronic viral hepatitis are the most common reported precipitating factors. An excessive systemic inflammatory response seems to play a crucial role in the development of ACLF. Using a liver-adapted sequential organ assessment failure score, it is possible to triage and prognosticate the outcome of patients with ACLF. The course of ACLF is dynamic and changes over the course of hospital admission.
'Acute On Chronic Liver Failure - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute On Chronic Liver Failure pipeline landscape is provided which includes the disease overview and Acute On Chronic Liver Failure treatment guidelines. The assessment part of the report embraces, in depth Acute On Chronic Liver Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute On Chronic Liver Failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Acute On Chronic Liver Failure R&D. The therapies under development are focused on novel approaches to treat/improve Acute On Chronic Liver Failure.
This segment of the Acute On Chronic Liver Failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute On Chronic Liver Failure Emerging Drugs
- HepaStem: Promethera Biosciences
- TAK-242: Akaza Bioscience
Further product details are provided in the report……..
Acute On Chronic Liver Failure: Therapeutic Assessment
This segment of the report provides insights about the different Acute On Chronic Liver Failure drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Acute On Chronic Liver Failure
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Acute On Chronic Liver Failure: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute On Chronic Liver Failure therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute On Chronic Liver Failure drugs.
Acute On Chronic Liver Failure Report Insights
- Acute On Chronic Liver Failure Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Acute On Chronic Liver Failure drugs?
- How many Acute On Chronic Liver Failure drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute On Chronic Liver Failure?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute On Chronic Liver Failure therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acute On Chronic Liver Failure and their status?
- What are the key designations that have been granted to the emerging drugs?
- Promethera Biosciences
- Akaza Bioscience
- RHEACELL
- Tianjin Weikai Bioeng., Ltd.
- Steminent Biotherapeutics Inc.
- Martin Pharmaceuticals, Inc.
- GNI Group Ltd.
- Versantis
- GENFIT
- HepaStem
- TAK-242
- APZ 2
- Stemchymal
- LIVANTRA
- F573
- VS-01
Introduction
Executive Summary
Acute On Chronic Liver Failure: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
HepaStem: Promethera Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
APZ 2: RHEACELL
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Acute On Chronic Liver Failure Key Companies
Acute On Chronic Liver Failure Key Products
Acute On Chronic Liver Failure- Unmet Needs
Acute On Chronic Liver Failure- Market Drivers and Barriers
Acute On Chronic Liver Failure- Future Perspectives and Conclusion
Acute On Chronic Liver Failure Analyst Views
Acute On Chronic Liver Failure Key Companies
Appendix
Executive Summary
Acute On Chronic Liver Failure: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
HepaStem: Promethera Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
APZ 2: RHEACELL
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Acute On Chronic Liver Failure Key Companies
Acute On Chronic Liver Failure Key Products
Acute On Chronic Liver Failure- Unmet Needs
Acute On Chronic Liver Failure- Market Drivers and Barriers
Acute On Chronic Liver Failure- Future Perspectives and Conclusion
Acute On Chronic Liver Failure Analyst Views
Acute On Chronic Liver Failure Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Acute On Chronic Liver Failure
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Acute On Chronic Liver Failure
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Acute On Chronic Liver Failure
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Acute On Chronic Liver Failure
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
